Elevance Health Inc.ELVNYSE
Loading
Elevance Health is the second-largest U.S. health insurer by revenue, operating Blue Cross Blue Shield plans in 14 states (including California, New York, Virginia, Georgia) serving 47 million medical members. The company generates revenue primarily through government-sponsored programs (Medicare Advantage, Medicaid) and commercial employer plans, with profitability driven by medical loss ratio management, membership growth, and its Carelon health services division providing pharmacy benefits, behavioral health, and care management solutions.
Elevance collects insurance premiums from members and government programs, then pays medical claims to providers. Profitability depends on maintaining medical loss ratios (MLR) below premium rates - typically targeting 85-87% MLR for commercial business and 88-90% for government programs. The company earns spread between premiums collected and claims paid, plus administrative fees. Carelon provides higher-margin services (pharmacy benefits management with drug rebates, utilization management, care coordination) that generate fee-based revenue. Scale advantages come from negotiating provider rates across 14-state footprint and leveraging data analytics for care management. Medicare Advantage growth is particularly attractive given aging demographics and 4-5% annual rate increases from CMS.
Medical Loss Ratio (MLR) performance versus guidance - 50-100 bps variance drives significant earnings beats/misses
Medicare Advantage membership growth and Star Ratings (affects bonus payments from CMS)
Medicaid redetermination impacts and state contract wins/losses across 29-state Medicaid footprint
Annual CMS rate updates for Medicare Advantage (typically announced in April)
Carelon health services revenue growth and margin expansion
Medical cost trend versus pricing adequacy - ability to price ahead of utilization increases
Medicare Advantage rate pressure from CMS policy changes - proposed 2024 rate cuts and Star Rating methodology changes threaten 200-300 bps margin compression
Political risk from single-payer healthcare proposals or public option expansion reducing private insurance market
Pharmacy cost inflation outpacing medical trend (specialty drugs growing 8-12% annually) pressuring Carelon PBM margins
Regulatory risk from MLR rebate requirements (80% commercial, 85% Medicare/Medicaid minimum) limiting pricing flexibility
UnitedHealth Group scale advantages in Medicare Advantage and vertical integration through Optum creating competitive disadvantage
Provider-sponsored health plans (Kaiser, UPMC) bypassing traditional insurers through direct-to-employer models
Amazon/CVS/Walmart primary care initiatives potentially disintermediating managed care in select markets
Medicare Advantage market saturation in core geographies with 15+ competitors in major metro markets
Reserve adequacy risk if medical cost trends accelerate unexpectedly - 100 bps MLR miss equals $2 billion claims shortfall
Goodwill impairment risk ($19+ billion from acquisitions) if Carelon growth disappoints or multiples compress
moderate - Government programs (55% of revenue) provide counter-cyclical stability as Medicaid enrollment increases during recessions. Commercial membership is cyclically sensitive to employment levels, but large employer base provides relative stability. Utilization patterns show modest pro-cyclical behavior as consumers defer elective procedures during downturns, temporarily improving MLR. However, recession-driven unemployment reduces commercial membership and shifts mix toward lower-margin Medicaid.
Moderate sensitivity through investment portfolio (approximately $30-35 billion in fixed-income securities backing reserves). Rising rates increase investment income on float, providing 5-10% earnings tailwind when rates rise 100 bps. However, higher rates compress valuation multiples for healthcare stocks. Minimal direct debt refinancing risk given modest 0.73x debt-to-equity ratio. Rate environment also affects M&A valuations for Carelon acquisitions.
Minimal direct credit exposure. Company holds investment-grade bond portfolio backing claim reserves. Primary credit risk is provider solvency (hospital systems, physician groups) which could disrupt network adequacy during severe downturns. Medicaid reimbursement depends on state budget health, creating indirect exposure to municipal credit conditions.
value - Stock trades at 0.4x P/S and 10.3x EV/EBITDA, below historical 12-14x range, attracting value investors seeking mean reversion. Defensive characteristics (government revenue, essential service) appeal to risk-averse investors. 4.1% FCF yield supports dividend growth investors. Recent -12.7% one-year return reflects regulatory concerns creating entry point for contrarians.
moderate - Beta typically 0.7-0.9 given defensive healthcare characteristics. Quarterly earnings volatility driven by MLR fluctuations (50-100 bps swings common). Regulatory announcements (CMS rates, policy changes) create event-driven volatility. Less volatile than biotech/devices but more volatile than utilities.